To compare three options for the elective treatment of portal hypertension during a 10-year period.
Variceal bleeding is the most feared complication of portal hypertension, leading to a considerable number of deaths and complications in almost all countries. There is no single therapeutic modality effective for all patients. After the bleeding episode, recurrence occurs in two thirds of the patients. 1, 2 There are several long-term treatment alternatives for patients who survive the bleeding episode. The therapeutic modalities now available for the bleeding-free interval are pharmacotherapy, 3 transendoscopic sclerotherapy and ligation, 4 transjugular intrahepatic portosystemic shunts, 5 surgical shunts, 6 and devascularization, 7 as well as liver transplantation. 8 Several studies have been designed to compare these alternatives, showing a variety of short-and long-term results. 9 -12 In this article we report the result of a prospective, controlled, randomized trial comparing ␤-blockers, transendoscopic sclerotherapy, and surgery for the elective treatment of bleeding portal hypertension.
METHODS
A comparative, longitudinal, prospective, controlled, randomized, and open trial was designed. Patients selected for the study were those who survived one or more proven variceal hemorrhage episodes assessed by endoscopy. Patients with a source of bleeding other than portal hypertension (gastric or duodenal ulcers together with varices) were excluded. Patients were randomized according to a random number table. Patients selected for randomization were classified according to the cause of portal hypertension as well as the Child-Pugh classification. To ensure that patients were uniformly distributed, randomization was done in blocks. Using sealed envelopes, patients were randomized to one of the three alternatives. When patients were selected for surgery, an angiogram was performed. Signed consent was obtained from all patients, and the study was approved by the hospital ethics committee. Patients were seen every 3 months after treatment in the outpatient clinic.
Patients were of either sex and age 18 to 75 years. They had a history of bleeding in the previous 6 months and at least 7 days without hemorrhage before randomization. They had not received previous treatment. Pregnant and lactating women were excluded. Additional exclusion criteria were as follows for the three groups: Patients randomized to surgery were treated by portal blood flow-preserving procedures (selective shunt, Sugiura-Futagawa operation).
Patients randomized to sclerotherapy were treated with paravariceal injections of a 5% urea-quinine solution. The sclerotherapy session was repeated each week, with an average of five sessions per patient.
In patients randomized to pharmacotherapy, portal pressure was measured. Patients then received ␤-blockers (propranolol) every 12 hours by mouth; the dose was adjusted until a 25% reduction in basal heart rate was obtained.
Survival and recurrence of bleeding were the main parameters of treatment evaluation. Patients were excluded from the study if rebleeding was found, and an alternate mode of therapy was started. Failure was defined as one episode of bleeding (hematemesis or melena) requiring hospital admission and transfusions as well as other forms of therapy with a reduction of systolic pressure (Ͻ20 mmHg) and an increase in cardiac rate (Ͼ20 per minute).
The exact Fisher test, the chi-square test, and analysis of variance were used for comparative analysis of the data. For long-term survival comparison, the log-rank test and the Wilcoxon test were used.
RESULTS
One hundred nineteen patients were included and randomized into three groups: surgical group (n ϭ 33), sclerotherapy group (n ϭ 46), and ␤-blocker group (n ϭ 40). Median follow-up overall was 45 months (range 0 -120). Patients lost to follow-up were included as the last clinical status available in their files. Table 1 shows the demo-graphic data of the patients. The three groups were comparable, and no differences were found among them.
Surgery Group
Of the 33 patients, 3 did not undergo surgery. One of them refused the operation after randomization and was treated by sclerotherapy; this patient died of rebleeding. The other two patients experienced deterioration of liver function after randomization and were considered high-risk patients. The remaining patients were treated with portal blood flow-preserving procedures: 20 with the Sugiura-Futagawa operation and 10 with selective shunts (nine distal splenorenal and one splenocaval). The surgical procedures were selected after angiography according to each patient's anatomical circumstances. Five of the 30 patients had rebleeding and were considered as failures (16.67% mean). Ten patients died: two from the Child A group, one from the Child B group, and seven from the Child C group.
In the Child A group, there were 2 surgical deaths (9%) and 10 late deaths (6 resulting from liver failure, 2 from hepatic carcinoma, and 2 from sepsis). Five patients were lost to follow-up and five patients are alive and well. Only one Child A patient had rebleeding. There was one death at long-term follow-up in the Child B group.
Sclerotherapy Group
Of the 46 patients, 21 were in Child A and 25 were in Child B or C. A total of 29 had rebleeding (63.03%), and 8 were rescued by surgery. Eighteen patients were lost to follow-up, and another 18 were recorded as late deaths as a result of liver failure or rebleeding. The remaining 10 are alive, including the 8 patients rescued by surgery.
␤-Blocker Group
Of the 40 patients, 22 were in Child A and 18 in Child B or C. A total of 31 had rebleeding (77.5%), 17 from Child A and 14 from Child B or C group. Twelve patients were lost to follow-up, and late deaths occurred in 24 cases. Four patients are alive. 
Group Comparisons
No differences were found in terms of age, Child-Pugh classification, or cause of liver disease. The rebleeding rate was lowest in the surgery group (16.67% vs. 63.04% for sclerotherapy and 77.5% for pharmacotherapy); the difference was significant (P Ͻ .0001). When only low-risk patients were analyzed (Child A), rebleeding was found in 5% of patients in the surgery group versus 71.42% in the sclerotherapy group and 68.18% in the pharmacotherapy group (Table 2) . Survival was best for the low-risk patients (Child A) in the three groups (P Ͻ .00002), but when compared, low-risk (Child A) and high-risk (Child B-C) patients showed no significant differences (log-rank test, P Ͻ .01; Wilcoxon, P Ͻ .06) ( Fig. 1) .
DISCUSSION
No single therapy has proven to be effective for all patients with bleeding portal hypertension. Several alternatives have been developed, and each seems to be applicable to a certain subset of patients.
Several clinical trials comparing sclerotherapy and pharmacotherapy 9 as well as sclerotherapy and surgery 11, 12 have been performed. The results vary according to the hospitals where the trials were conducted and the patient populations analyzed. To our knowledge, this is the first prospective, controlled, and randomized trial that compares the three therapeutic alternatives in a heterogeneous group of patients with diverse hepatopathies (nevertheless, the groups were comparable with each other).
In the past decade, several studies comparing shunts with sclerotherapy have been published. [13] [14] [15] Four of these studies used selective shunts. They showed a low rebleeding rate for shunt surgery and different survival patterns. Rebleeding is found consistently in 30% and 60% of patients undergoing sclerotherapy.
Our results show that surgery (portal blood flow-preserving procedures) is the treatment of choice for low-risk patients undergoing elective surgery. Patients in the surgery group had the lowest rebleeding rate in all Child classes in this trial.
Several authors have documented a low rebleeding rate after surgery as well as a high rebleeding rate after sclerotherapy and pharmacotherapy. The results of our study do not differ from those obtained in other trials. The death rate was high among the three groups after 72 months. Fifty-nine of 123 patients died. There were seven surgical deaths, and the other 52 died of rebleeding or liver failure. No differences in survival were shown among the three groups in this study, although the sclerotherapy and pharmacotherapy groups included the patients rescued with surgery.
We attribute the better results obtained in the surgery group to the following: Elective treatment of patients with a history of variceal bleeding (secondary prophylaxis) is not the best setting for sclerotherapy and pharmacotherapy. Several studies have shown a high rebleeding rate in patients treated with these options.
Liver transplantation has gained a major role in developed countries as a treatment modality for patients with portal hypertension and end-stage liver disease. 16 It is a procedure that should be reserved for patients in whom liver failure (Child C) is associated with variceal bleeding. Although the populations are not comparable, better results in terms of surgical deaths and survival have been observed in low-risk patients treated by shunt surgery. 17 Rikkers et al 18 have suggested that shunt surgery should be used as a long-term bridge for liver transplantation in these patients. Surgery (portal blood flow-preserving procedures) is the treatment of choice for patients with good liver function undergoing elective surgery.
Today, a thorough trial should include transjugular intra- hepatic portosystemic shunts, variceal banding, liver transplantation, portal blood flow-preserving procedures, and combined pharmacotherapy. Each of these therapies has a defined role in a certain subset of patients and complements each other in the treatment of patients with bleeding portal hypertension.
